글로벌 인간 면역 결핍 바이러스(HIV) 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

인간 면역 결핍 바이러스(HIV) 시장 분석

(HIV) 시장은 진단, 치료 옵션의 발전, 질병에 대한 인식 증가에 힘입어 상당한 성장을 경험했습니다. 주요 추세에는 항레트로바이러스 요법(ART), 특히 바이러스 부하를 효과적으로 억제하고 환자 결과를 개선하는 고활성 항레트로바이러스 요법(HAART)의 채택 증가가 포함됩니다. 최근 개발은 장기 작용 주사제와 약물 용출 기술의 출현을 강조하며, 이는 투여 빈도를 줄여 치료 준수를 향상시킵니다. 또한 신속한 항원/항체 검사 및 핵산 검사와 같은 진단 도구의 혁신을 통해 HIV를 더 일찍 발견하고 더 잘 관리할 수 있습니다. 시장은 또한 전염 위험을 크게 낮추는 노출 전 예방(PrEP)을 포함한 예방 조치로의 전환을 목격하고 있습니다.

인간 면역 결핍 바이러스(HIV) 시장 규모

글로벌 인간 면역 결핍 바이러스(HIV) 시장 규모는 2023년에 347억 2천만 달러로 평가되었으며, 2031년까지 561억 9천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 6.20%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

인간 면역 결핍 바이러스(HIV) 시장 동향

“치료 및 진단 기술의 발전 ”

시장은 치료 및 진단 기술의 발전으로 인해 혁신적인 변화를 겪고 있습니다. 중요한 추세는 장기 작용 항레트로바이러스 요법(ART)의 채택이 증가하고 있는 것입니다. 이는 환자에게 투여 빈도를 줄여 더 편리한 치료 옵션을 제공하여 준수와 전반적인 건강 결과를 개선합니다. 주사형 제형 및 이식형 장치와 같은 혁신은 이러한 장기 작용 치료법의 길을 열어 개인이 일상 생활을 최소한으로 방해하면서 바이러스 억제를 유지할 수 있도록 합니다. 또한 신속한 항원/항체 검사 및 재택 검사 키트를 포함한 향상된 진단 도구를 통해 조기에 감지하고 시기적절한 개입을 용이하게 합니다. HIV에 대한 인식이 높아지고 의료 서비스 제공자가 환자 중심적 접근 방식을 우선시함에 따라 시장은 효과적인 치료와 포괄적인 지원 서비스를 결합한 통합 치료 모델로 전환되고 있습니다. 이러한 진화하는 환경은 HIV 관리를 개선하고 낙인을 줄이고 바이러스에 감염된 사람들의 건강을 증진하는 것을 목표로 합니다.

보고서 범위 및 인간 면역 결핍 바이러스(HIV) 시장 세분화

Human Immunodeficiency Virus (HIV) Market Definition

HIV is a virus that attacks the body's immune system, specifically targeting CD4 cells, which are crucial for maintaining a healthy immune response. If left untreated, HIV can lead to Acquired Immunodeficiency Syndrome (AIDS), a condition characterized by a severely weakened immune system, making individuals vulnerable to opportunistic infections and certain cancers. HIV is primarily transmitted through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding. While there is no cure for HIV, advancements in antiretroviral therapy (ART) have transformed the disease into a manageable chronic condition, allowing individuals to live longer, healthier lives. Early diagnosis and consistent treatment are essential for suppressing the virus and preventing transmission, highlighting the importance of awareness, education, and access to healthcare services in combating the HIV epidemic.

Human Immunodeficiency Virus (HIV) Market Dynamics

Drivers

• Rising Number of HIV Cases Globally

The rising number of HIV cases globally highlights an urgent need for effective treatment and prevention strategies, significantly fueling market growth. According to the World Health Organization (WHO), approximately 39.9 million people were living with HIV at the end of 2023, of which. 1.4 million children (0–14 years old). This alarming trend emphasizes the importance of advancing treatment options, such as antiretroviral therapy (ART), which can effectively manage the virus and improve the quality of life for those affected. In addition, increasing awareness campaigns and educational initiatives are vital to promoting preventive measures like pre-exposure prophylaxis (PrEP) and regular testing. As healthcare systems respond to this growing challenge, the demand for innovative solutions and comprehensive care continues to drive significant advancements in the HIV market, creating opportunities for growth and development in the sector.

• Innovations in Antiretroviral Therapies (ART)

Innovations in antiretroviral therapies (ART) serve as a significant market driver in the HIV treatment landscape, enhancing treatment efficacy and patient adherence. Long-acting injectables, for instance, allow patients to receive medication less frequently, often on a monthly or quarterly basis, thereby reducing the burden of daily pill-taking and improving adherence rates. This is particularly beneficial for individuals who may struggle with the complexities of daily regimens. In addition, the development of new drug combinations targets the virus more effectively while minimizing side effects, further improving patient outcomes. As healthcare providers deliver more personalized care that aligns with individual needs, the demand for these innovative treatment options continues to grow. Consequently, the advancement of ART is improving health outcomes for patients and driving significant growth in the HIV market.

Opportunities

• Emergence of Long-Acting Therapies

The development of long-acting antiretroviral therapies (ART) represents a significant advancement in HIV treatment, particularly through the introduction of injectable formulations and implantable devices. These innovative therapies offer the potential for improved patient adherence by reducing the frequency of dosing, allowing patients to receive treatment monthly or even quarterly, rather than daily. This convenience addresses common challenges associated with daily pill regimens, such as forgetfulness and treatment fatigue. Furthermore, long-acting therapies can enhance viral suppression and reduce the risk of transmission, contributing to better health outcomes. As healthcare providers adopt these therapies, patients benefit from more flexible treatment options that fit their lifestyles. This evolution in ART improves adherence and expands market reach by appealing to a broader range of patients seeking effective and manageable HIV care solutions.

• Advancements in Diagnostic Technologies

Innovations in rapid testing and point-of-care diagnostics represent a significant market opportunity in the HIV healthcare landscape, enabling early detection and timely treatment. These advanced diagnostic tools allow healthcare providers to conduct tests quickly and efficiently, often delivering results within minutes. This immediacy facilitates prompt medical intervention and empowers patients with immediate information about their health status. Enhanced accessibility to testing, particularly in remote or underserved areas, further supports early diagnosis, which is critical for effective HIV management. In addition, the ease of use and minimal training required for point-of-care tests encourage widespread adoption among healthcare professionals. As demand for these innovative diagnostic solutions continues to grow, they present a valuable opportunity for market expansion, improving healthcare delivery and ultimately enhancing patient outcomes in the fight against HIV.

Restraints/Challenges

• Lack of Personalized Treatment Options

The need for more personalized treatment options in antiretroviral therapy (ART) serves as a significant market challenge in the management of HIV. While advancements in ART have improved overall treatment outcomes, each individual's response to medication can vary due to unique genetic and physiological differences. This variability highlights the limitations of a one-size-fits-all approach to treatment, as many patients may experience adverse effects or inadequate viral suppression with standard regimens. The lack of personalized medicine strategies, including pharmacogenomics, restricts the ability to identify the most effective therapies for each patient, complicating treatment adherence and management.

• Mental Health Barriers

The mental health challenges faced by many individuals living with HIV serve as a significant market restraint, adversely impacting treatment adherence and overall health outcomes. Conditions such as depression and anxiety often arise from the stigma associated with HIV, fear of discrimination, and the emotional toll of managing a chronic illness. These psychological barriers can diminish motivation, making it difficult for patients to maintain consistent medication regimens or attend necessary healthcare appointments. Furthermore, anxiety can heighten feelings of uncertainty and distress, complicating adherence to treatment plans. This cycle of neglect affects individual health and places additional strain on healthcare systems. Therefore, addressing these mental health challenges through integrated care models that encompass psychological support and counseling is essential. Failure to do so restricts the effectiveness of HIV treatment efforts and hampers market growth, highlighting the need for comprehensive strategies that consider both physical and mental health aspects of patient care.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Human Immunodeficiency Virus (HIV) Market Scope

The market is segmented on the basis of diagnostics, drugs, route of administration, and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnostics

• Antigen/Antibody Test
• Antibody Test
• Nucleic Acid Tests (NATs)
• CD4T Cell Count
• Viral Load
• Drug Resistance
• Others

 Drugs

• Protease Inhibitors (PIs)
• Multi-Class Combination Drugs
• Fusion Inhibitors (FI)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

 Human Immunodeficiency Virus (HIV) Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, diagnostics, drugs, route of administration, and end-users as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has experienced steady growth in the human immunodeficiency virus (HIV) market during the forecast period, driven by rising healthcare and research and development investments. Increased patient awareness and the involvement of major market players in developing novel technologies and reformulating existing drugs are significant contributors to this expansion. These elements collectively enhance the landscape of the HIV market, promoting innovation and accessibility. As a result, the overall growth trajectory of the HIV market remains promising.

Asia-Pacific region leads the human immunodeficiency virus (HIV) market, primarily due to the high incidence of HIV/AIDS cases and the availability of numerous generic drugs. In addition, the increasing investment in the healthcare sector is significantly driving market growth. The burgeoning populations in India and China are expected to further escalate the demand for HIV medications in the coming years. This combination of factors positions the Asia-Pacific market for continued expansion and innovation in HIV treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Human Immunodeficiency Virus (HIV) Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 인간 면역 결핍 바이러스(HIV) 시장 리더는 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 아스트라제네카(영국)
• GSK plc (영국)
• 머크앤코(미국)
• 노바티스 AG(스위스)
• 파이저 주식회사(미국)
• Sun Pharmaceutical Industries Ltd. (인도)
• 마일런 NV(미국)
• 사노피(프랑스)
• Bayer AG(독일)
• 제넨텍 주식회사(미국)

인간 면역 결핍 바이러스(HIV) 시장의 최신 동향

• 2022년 8월, 길리드 사이언스는 유럽 위원회(EC)에서 Sunlenca(Lenacapavir)에 대한 최초의 글로벌 규제 승인을 발표하면서 중요한 이정표를 달성했습니다. 주사와 정제 형태로 제공되는 이 획기적인 치료법은 다중 약물 내성 HIV 감염 환자를 위해 특별히 설계되었습니다. Sunlenca는 다른 항레트로바이러스 요법과 함께 사용하여 선택의 폭이 제한된 환자의 치료 옵션을 개선하도록 설계되었습니다. 이 승인은 HIV와의 싸움에서 중요한 진전을 나타내며 치료 내성으로 어려움을 겪는 환자에게 새로운 희망을 제공합니다.

SKU-52656